Latest filings (excl ownership)
6-K
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
24 Apr 24
20-F
2023 FY
Annual report (foreign)
24 Apr 24
6-K
Current report (foreign)
17 Apr 24
6-K
Voting Rights and Shares Capital of the Company
10 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Nanobiotix to Present at Upcoming Investor Conferences in March
6 Mar 24
6-K
Voting Rights and Shares Capital of the Company
13 Feb 24
6-K
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
31 Jan 24
6-K
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
29 Jan 24
6-K
Voting Rights and Shares Capital of the Company
11 Jan 24
6-K
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
26 Dec 23
6-K
Voting Rights and Shares Capital of the Company
13 Dec 23
6-K
Current report (foreign)
4 Dec 23
6-K
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
13 Nov 23
6-K
Current report (foreign)
9 Nov 23
6-K
Voting Rights and Shares Capital of the Company
9 Nov 23
6-K
NANOBIOTIX Announces Closing of Global Offering
8 Nov 23
6-K
Current report (foreign)
7 Nov 23
424B5
Prospectus supplement for primary offering
6 Nov 23
FWP
Free writing prospectus
2 Nov 23
6-K
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
2 Nov 23
FWP
Free writing prospectus
2 Nov 23
424B5
Prospectus supplement for primary offering
1 Nov 23
6-K
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
1 Nov 23
6-K
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data
23 Oct 23
6-K
Voting Rights and Shares Capital of the Company
11 Oct 23
6-K
Current report (foreign)
4 Oct 23
6-K
Current report (foreign)
29 Sep 23
6-K
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
28 Sep 23
6-K
Current report (foreign)
26 Sep 23
6-K
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
26 Sep 23
6-K
Current report (foreign)
19 Sep 23
6-K
Voting Rights and Shares Capital of the Company
13 Sep 23
6-K
NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
5 Sep 23
6-K
NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
31 Aug 23
6-K
Current report (foreign)
15 Aug 23
6-K
NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
4 Aug 23
6-K
Voting Rights and Shares Capital of the Company
20 Jul 23
6-K
Current report (foreign)
19 Jul 23
6-K
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
10 Jul 23
Latest ownership filings
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G/A
Qatar Investment Authority
8 Feb 24
SC 13G/A
JOHNSON & JOHNSON
2 Feb 24
SC 13G/A
BAILLIE GIFFORD & CO
29 Jan 24
SC 13G
Johnson & Johnson Innovation - JJDC, Inc.
16 Nov 23
SC 13G
Qatar Investment Authority
8 Nov 23
SC 13G/A
BAILLIE GIFFORD & CO
2 Feb 23
SC 13G/A
BAILLIE GIFFORD & CO
20 Jan 23
SC 13G/A
Artal International S.C.A.
11 Feb 22
SC 13G/A
BAILLIE GIFFORD & CO
26 Jan 22
SC 13G/A
Artal International S.C.A.
16 Feb 21
SC 13G
BAILLIE GIFFORD & CO
27 Jan 21
SC 13G
Artal International S.C.A.
28 Dec 20